68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

Loading...
Thumbnail Image

Authors

Sathekge, Mike Machaba
Lengana, Thabo
Modiselle, Moshe
Vorster, Mariza
Zeevaart, Jan Rijn
Maes, Alex
Ebenhan, Thomas
Van de Wiele, Christophe

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

Abstract

BACKGROUND : To report on imaging findings using 68Ga-PSMAHBED- CC PET in a series of 19 breast carcinoma patients. METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. RESULTS : Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptornegative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p= 0.015). CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.

Description

Keywords

68Ga-PSMA, PET/CT, Breast cancer, Prostate-specific membrane antigen (PSMA), Positron emission tomography (PET)

Sustainable Development Goals

Citation

Sathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6.